Issue navigation
Volume 26, Issue Supplement_5, October 2024
Abstracts from the 19th Meeting of the European Association of Neuro-Oncology
ORAL PRESENTATIONS
PL01 Brain connectome: implications for brain tumors and their treatments
PL01.4.A COMPUTATIONAL HISTOPATHOLOGY ENABLES HIGH-GRANULARITY DIAGNOSTICS IN CNS TUMOURS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v1, https://doi.org/10.1093/neuonc/noae144.001
PL01.5.A ASSOCIATION BETWEEN RESTING-STATE-NETWORK FUNCTIONAL CONNECTIVITY AND SURVIVAL IN RECURRENT GLIOMAS DIAGNOSED USING FET PET
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v1, https://doi.org/10.1093/neuonc/noae144.002
PL02 Late Breaking Abstracts
PL02.1.A LOCOREGIONAL BI-SPECIFIC CAR-T CELLS TARGETING CD44 AND CD133 IN RECURRENT GLIOBLASTOMA: THE INTERIM RESULTS OF THE FIRST IN-HUMAN CLINICAL TRIAL
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v1–v2, https://doi.org/10.1093/neuonc/noae144.003
PL02.2.A TRAMETINIB IN NEUROFIBROMATOSIS TYPE 1 RELATED SYMPTOMATIC PLEXIFORM NEUROFIBROMAS: ONE-YEAR FOLLOW-UP OF THE TRAIN STUDY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v2, https://doi.org/10.1093/neuonc/noae144.004
PL02.3.A MOLECULAR CLASSIFICATION TO REFINE SURGICAL AND RADIOTHERAPEUTIC DECISION MAKING IN MENINGIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v2, https://doi.org/10.1093/neuonc/noae144.005
KS01 Boosting immune responses in the brain
KS01.4.A CHARACTERIZATION AND THERAPEUTIC TARGETING OF ASTROCYTE REACTIVITY STATES DURING PROGRESSION FROM PRIMARY TO POST-RADIOTHERAPY RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v2–v3, https://doi.org/10.1093/neuonc/noae144.006
KS01.5.A A BRAIN CANCER CELL ATLAS REVEALS SHARED ASTROCYTE-LIKE STEM CELL STATES DRIVE INTRATUMOURAL HETEROGENEITY AND SHAPE IMMUNE DYNAMICS IN ADULT-TYPE DIFFUSE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v3, https://doi.org/10.1093/neuonc/noae144.007
KS01.6.A THE LIPID DROPLET PHENOTYPE AS A TARGETABLE METABOLIC DEPENDENCY OF TUMOR CELLS AND PRO-TUMORAL MACROPHAGES IN THE PERI-NECROTIC GBM NICHE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v3, https://doi.org/10.1093/neuonc/noae144.008
KS02 IDH inhibitors: clinical and molecular insights
KS02.5.A THE ONCOMETABOLITE D-2-HYDROXYGLUTARATE PROMOTES DNA HYPERMETHYLATION AT LINEAGE-SPECIFIC ENHANCERS CONTROLLING MICROGLIAL ACTIVATION IN IDH-MUTATED GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v3–v4, https://doi.org/10.1093/neuonc/noae144.009
KS02.6.A SINGLE-CELL MULTIMODAL ANALYSIS OF IDH-MUTANT GLIOMAS UNCOVERS SHIFT FROM EPIGENETIC TO GENETIC DRIVERS WITH TUMOR PROGRESSION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v4, https://doi.org/10.1093/neuonc/noae144.010
KS02.7.A LONGITUDINAL SINGLE-CELL ANALYSES IDENTIFY DRIVERS OF GENETIC, EPIGENOMIC, AND CELLULAR EVOLUTION IN IDH-MUTANT GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v4, https://doi.org/10.1093/neuonc/noae144.011
KS03 Breaking the walls: efforts to democratize access to clinical information
KS03.4.A PATTERNS OF CARE AND CLINICAL OUTCOMES OF PATIENTS WITH GLIOBLASTOMA IN THE UNITED STATES FROM 2005-2020: A REAL-WORLD ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v5, https://doi.org/10.1093/neuonc/noae144.012
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v5, https://doi.org/10.1093/neuonc/noae144.013
KS03.6.A TUMOR-SPECIFIC B CELL RESPONSE IN THE CEREBROSPINAL FLUID OF MELANOMA PATIENTS: RECOMBINANT ANTIBODIES SPECIFICALLY BIND TO THE TUMOR-ASSOCIATED ANTIGENS DDX53, AKR1A AND KIFC3
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v5, https://doi.org/10.1093/neuonc/noae144.014
KS04 Molecular insights into oligodendrogliomas
KS04.5.A DIFFERENCES IN COGNITIVE FUNCTIONING BETWEEN PATIENTS WITH IDH1-MUTANT OLIGODENDROGLIOMA AND ASTROCYTOMA BEFORE AND AFTER SURGERY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v6, https://doi.org/10.1093/neuonc/noae144.015
KS04.6.A GLIOMAS WITH PLEOMORPHIC AND PSEUDOPAPILLARY FEATURES (GPAP) ARE CIRCUMSCRIBED TUMORS WITH LONG-TERM SURVIVAL
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v6, https://doi.org/10.1093/neuonc/noae144.016
KS04.7.A HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v6–v7, https://doi.org/10.1093/neuonc/noae144.017
KS05 Cellular-based immunotherapies
KS05.5.A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v7, https://doi.org/10.1093/neuonc/noae144.018
KS05.6.A T-CELL THERAPY COMBINED WITH LOW-INTENSITY PULSED FOCUSED ULTRASOUND, MICROBUBBLES AND POLY-ICLC PROMOTES THE PRESENTATION OF BRAIN-DERIVED ANTIGENS, BREAKING CNS TOLERANCE AND INDUCING ACTIVE T-CELL RESPONSES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v7–v8, https://doi.org/10.1093/neuonc/noae144.019
KS05.7.A INTRATHECAL DELIVERY OF PEPTIDE-PULSED TYPE 1 CONVENTIONAL DENDRITIC CELL VACCINE IS HIGHLY EFFICACIOUS FOR THE TREATMENT OF BREAST CANCER-ASSOCIATED LEPTOMENINGEAL DISEASE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v8, https://doi.org/10.1093/neuonc/noae144.020
JS02 EANO-ESTRO: DNA repair inhibitors in glioma
JS02.5.A A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v8, https://doi.org/10.1093/neuonc/noae144.021
JS02.6.A PRELIMINARY SIGNS OF CLINICAL ACTIVITY OF TUVUSERTIB (M1774), A HIGHLY POTENT ORAL ATR INHIBITOR, IN REFRACTORY IDH MUTATED GLIOMA PATIENTS WITH P53 AND ATRX MUTATIONS; A CASE SERIES FROM A FIH STUDY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v8–v9, https://doi.org/10.1093/neuonc/noae144.022
JS02.7.A MAINTENANCE TEMOZOLOMIDE CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: DOES TIME OF ADMINISTRATION MATTER?
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v9, https://doi.org/10.1093/neuonc/noae144.023
JS03 EANO Youngsters-SIOP: Uniting frontiers against pediatric and adult brain tumors
JS03.5.A DO PATIENTS WITH MOLECULARLY-DEFINED GLIOBLASTOMA SHARE THE SAME CLINICAL CHARACTERISTICS AND OUTCOME OF HISTOLOGICALLY-DEFINED GLIOBLASTOMA? A MULTICENTRIC STUDY FROM THE ITALIAN ASSOCIATION OF NEURO-ONCOLOGY (AINO)
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v9–v10, https://doi.org/10.1093/neuonc/noae144.024
JS03.6.A TUMOR ASSOCIATED MACROPHAGE DERIVED EXOSOMES MODULATE IMMUNOTHERAPEUTIC SENSITIVITY OF SHH MEDULLOBLASTOMA BY TARGETING M6A MODIFIED FOXD1
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v10, https://doi.org/10.1093/neuonc/noae144.025
JS03.7.A COMBINATION OF CDK4/6 AND MEK INHIBITION INCREASES ANTITUMOR EFFECTS IN PEDIATRIC HIGH-GRADE GLIOMA HARBORING BRAF MUTATION AND CDKN2A/B LOSS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v10, https://doi.org/10.1093/neuonc/noae144.026
JS04 EANO-EANS: Clinical trials in surgical neuro-oncology
JS04.4.A SHORTENING THE TURNAROUND TIME FROM SURGERY TO COMPLETE MOLECULAR DIAGNOSIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v10, https://doi.org/10.1093/neuonc/noae144.027
JS04.5.A THE ROLE OF SURGERY IN IDH WILDTYPE DIFFUSE ASTROCYTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v11, https://doi.org/10.1093/neuonc/noae144.028
JS04.6.A EVOLUTION OF GLIOBLASTOMA THERAPY IN TWO DECADES: COMPARISON OF TWO PROSPECTIVE, CONTROLLED TRIALS ON THE RESECTION OF GLIOBLASTOMA: THE 5-ALA AND IMRI VS. 5-ALA-TRIALS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v11, https://doi.org/10.1093/neuonc/noae144.029
JS05 EANO-SNO: Translational Advances for Meningiomas
JS05.5.A INCIDENTAL MENINGIOMA: RESULTS FROM THE IMPACT INTERNATIONAL MULTICENTRE STUDY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v11, https://doi.org/10.1093/neuonc/noae144.030
JS05.6.A THE PROGNOSTIC IMPACT OF CDKN2A/B HETEROZYGOUS DELETIONS IN MENINGIOMA- INSIGHTS OF A MULTICENTER ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v12, https://doi.org/10.1093/neuonc/noae144.031
JS05.7.A TRAF7 WD40-DOMAIN MUTATIONS DRIVE MENINGIOMA TRANSDIFFERENTIATION AND INTRATUMOR HYPEROSTOSIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v12, https://doi.org/10.1093/neuonc/noae144.032
JS06 EANO-EANM: Therapy of meningioma
JS06.4.A RADIOTHERAPY QUALITY ASSURANCE IN THE ROAM/EORTC1308 ATYPICAL MENINGIOMA RANDOMISED CONTROLLED TRIAL: PROSPECTIVE REVIEW IMPROVES RADIOTHERAPY QUALITY AND CONSISTENCY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v12, https://doi.org/10.1093/neuonc/noae144.033
JS06.5.A MERTK ON TUMOUR CELLS AND MACROPHAGES: A THERAPEUTIC OPTION FOR NF2-RELATED AND SPORADIC MENINGIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v12–v13, https://doi.org/10.1093/neuonc/noae144.034
JS06.6.A COPENHAGEN GRADING FOR MENINGIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v13, https://doi.org/10.1093/neuonc/noae144.035
JS07 EANO-EACR: Navigating preclinical approaches to identify windows of opportunity and develop clinical trials
JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v13, https://doi.org/10.1093/neuonc/noae144.036
JS07.5.A CORRELATION BETWEEN TUMOR-INFILTRATING LYMPHOCYTE DISTRIBUTION AND CLINICAL OUTCOME IN PHASE I/II CLINICAL TRIAL OF DENDRITIC-CELL BASED IMMUNOTHERAPY IN GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v13, https://doi.org/10.1093/neuonc/noae144.037
JS07.6.A MULTI-OMICS AND DRUG RESPONSE ASSESSMENTS IN LONGITUDINAL PATIENT AVATARS UNVEIL PATIENT-SPECIFIC RECURRENCE TRAJECTORIES AND DRUG SUSCEPTIBILITIES IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v13–v14, https://doi.org/10.1093/neuonc/noae144.038
JS08 EANO-ESNR: Progress in MR imaging for brain tumor diagnosis and monitoring
JS08.5.A AMINO-ACID PET VERSUS MRI GUIDED RE-IRRADIATION IN PATIENTS WITH RECURRENT GLIOBLASTOMA - GLIAA TRIAL (NOA 10/ARO 2013-1, DKTK-A)
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v14, https://doi.org/10.1093/neuonc/noae144.039
JS08.6.A SYNTHETIC [18F]FET-PET GENERATION AND HOTSPOT PREDICTION VIA PREOPERATIVE MRI OF GLIOMA LACKING RADIOGRAPHIC HIGH-GRADE CHARACTERISTICS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v14–v15, https://doi.org/10.1093/neuonc/noae144.040
JS08.7.A SURGERY TRANSIENTLY DISRUPTS THE BLOOD BRAIN BARRIER OF THE GLIOBLASTOMA RESECTION MARGIN: OPPORTUNITIES FOR EARLY AND SELECTIVE POSTOPERATIVE TREATMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v15, https://doi.org/10.1093/neuonc/noae144.041
OS01 Update on Response Assessment in Neuro-Oncology (RANO): projects and milestones
OS01.4.A MODELING EGFR REGULATION IN GLIOBLASTOMA REVEALS ASSOCIATIONS WITH ITS LIGANDS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v15, https://doi.org/10.1093/neuonc/noae144.042
OS01.5.A MEASURABLE DISEASE AS BASELINE CRITERION FOR RESPONSE ASSESSMENT IN GLIOBLASTOMA TRIALS - A COMPARISON OF THE MRI-BASED (RANO 2.0) VERSUS PET-BASED (PET RANO 1.0) ASSESSMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v15, https://doi.org/10.1093/neuonc/noae144.043
OS02 Quality of Life and Symptom Management: state of the science
OS02.4.A CAREGIVER PROGRAM IN NEURO-ONCOLOGY: UCSF EXPERIENCE CARING FOR MORE THAN 4,000 CAREGIVERS OVER THE LAST 10 YEARS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v16, https://doi.org/10.1093/neuonc/noae144.044
OS02.5.A ASSESSING QUALITY OF LIFE IN BRAIN METASTASES PATIENTS AND THEIR CAREGIVERS UNDERGOING RADIOTHERAPY: A COMPARATIVE ANALYSIS WITH HEALTHY AND CANCER POPULATIONS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v16, https://doi.org/10.1093/neuonc/noae144.045
OS02.6.A COORDINATION OF CARE IN THE CONTEXT OF PRIMARY BRAIN TUMOURS: HEALTHCARE PROFESSIONALS’ EXPLORATION OF THE UNSPOKEN IMPACT AND CLINICAL IMPLICATIONS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v16, https://doi.org/10.1093/neuonc/noae144.046
OS03 Exploiting dormancy, senescence and their links with the immune system in brain tumors
OS03.4.A REPEATED INTRACRANIAL ADMINISTRATION OF ANTI-PD-1 ALONE OR IN COMBINATION WITH ANTI-CTLA-4 IMMUNE CHECKPOINT-BLOCKING MONOCLONAL ANTIBODIES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v17, https://doi.org/10.1093/neuonc/noae144.047
OS03.5.A A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF AUTOLOGOUS CD1C(BDCA-1)+ /CD141(BDCA-3)+ MYELOID DENDRITIC CELLS IN COMBINATION WITH IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v17, https://doi.org/10.1093/neuonc/noae144.048
OS03.6.A MITOCHONDRIA TRANSFER IN GBM IS MEDIATED BY TGF-Β AND PROMOTES INCREASED INVASIVENESS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v17, https://doi.org/10.1093/neuonc/noae144.049
OS04 Navigating fertility/pregnancy in patients with primary brain tumours
OS04.5.A SEXUALITY IN PATIENTS WITH LOW-GRADE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v17–v18, https://doi.org/10.1093/neuonc/noae144.050
OS04.6.A ONE STEP CLOSER TO THE END OF LIFE - A QUALITATIVE STUDY ABOUT THE EXPERIENCES OF PATIENTS AND THEIR FAMILIES IN RELATION TO THE RECURRENCE OF A HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v18, https://doi.org/10.1093/neuonc/noae144.051
OS04.7.A PRESERVATION OF FERTILITY AND FAMILY PLANNING IN PATIENTS WITH LOW-GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v18, https://doi.org/10.1093/neuonc/noae144.052
OS05 Radiation necrosis: definition, diagnosis, management, prevention and future research
OS05.5.A DOSE ESCALATED SPINE RADIOSURGERY FOR RADIORESISTANT SPINAL METASTASES UTILIZING SIMULTANEOUS INTEGRATED BOOST
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v18–v19, https://doi.org/10.1093/neuonc/noae144.053
OS05.6.A RADIOLOGICAL TREATMENT-ASSOCIATED CHANGES IN GLIOBLASTOMAS WITH OR WITHOUT AN MGMT PROMOTER-METHYLATION TREATED WITH CILENGITIDE: REVIEW OF THE EORTC CENTRIC AND CORE STUDIES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v19, https://doi.org/10.1093/neuonc/noae144.054
OS05.7.A RADIATION-INDUCED CONTRAST ENHANCEMENT AFTER PROTON THERAPY IN PATIENTS WITH GLIOMAS IN THE PRO-CNS STUDY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v19, https://doi.org/10.1093/neuonc/noae144.055
OS06 Highlights from clinical abstracts
OS06.1.A UTILITY OF CIRCULATING TUMOR DNA (CTDNA) FROM CEREBROSPINAL FLUID (CSF) FOR PROGNOSIS OF PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v19–v20, https://doi.org/10.1093/neuonc/noae144.056
OS06.2.A RENEU: A PIVOTAL PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA (PN)
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v20, https://doi.org/10.1093/neuonc/noae144.057
OS06.3.A EFFECT OF EARLY INTEGRATION OF PALLIATIVE CARE ON THE QUALITY OF LIFE IN GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v20, https://doi.org/10.1093/neuonc/noae144.058
OS06.4.A NEURO-ONCOLOGICAL SUPERIORITY OF SUPRATOTAL RESECTION AGAINST TOTAL RESECTION FOR IDH-MUTANT LOWER-GRADE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v20–v21, https://doi.org/10.1093/neuonc/noae144.059
OS06.5.A ACCURATE AND COMPREHENSIVE EVALUATION OF MGMT PROMOTER METHYLATION BY NANOPORE SEQUENCING
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v21, https://doi.org/10.1093/neuonc/noae144.060
OS06.6.A LOCAL DELIVERY OF HRBMP4 AS AN ANTICANCER THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION TRIAL
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v21, https://doi.org/10.1093/neuonc/noae144.061
OS06.7.A PLATFORM-AGNOSTIC METHYLATION CLASSIFICATION OF 184 CLASSES OF CNS TUMOURS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v21–v22, https://doi.org/10.1093/neuonc/noae144.062
OS06.8.A PROSPECTIVE STUDY ON THE IMPACT OF THE GUT MICROBIOME COMPOSITION TO PATIENT’S RESPONSE TO STANDARD TREATMENT IN PCNSL
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v22, https://doi.org/10.1093/neuonc/noae144.063
OS06.9.A A PHASE 0/1 ‘TRIGGER’ TRIAL OF BDTX-1535 IN RECURRENT HIGH-GRADE GLIOMA (HGG) PATIENTS WITH EGFR ALTERATIONS OR FUSIONS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v22, https://doi.org/10.1093/neuonc/noae144.064
OS07 Highlights from preclinical abstracts
OS07.1.A INTEGRATIVE SINGLE NUCLEI, SPATIAL, AND FUNCTIONAL GENOMIC ANALYSES REVEAL DNA-PK DRIVES GLIOBLASTOMA RADIORESISTANCE THROUGH TUMOR CELLS AND THE MYELOID MICROENVIRONMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v22–v23, https://doi.org/10.1093/neuonc/noae144.065
OS07.2.A INTEGRATED SPATIALLY RESOLVED TRANSCRIPTOMICS AND ELECTROPHYSIOLOGY UNRAVELED THE ARCHITECTURAL HETEROGENEITY OF NEURONAL-GLIOMA INTERFACES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v23, https://doi.org/10.1093/neuonc/noae144.066
OS07.3.A DYNAMIC METABOLIC SHIFTS RESHAPE GLIOBLASTOMA: IMPACTS ON SPATIAL STRUCTURE AND IMMUNE RESPONSE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v23, https://doi.org/10.1093/neuonc/noae144.067
OS07.4.A INTERLEUKIN-6 INCREASES STRUCTURAL AND ELECTROPHYSIOLOGICAL CONNECTIVITY IN GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v23, https://doi.org/10.1093/neuonc/noae144.068
OS07.5.A MULTI-MODAL EXAMINATION OF SPATIAL HETEROGENEITY IN THE ASTROCYTOMA MICROENVIRONMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v23–v24, https://doi.org/10.1093/neuonc/noae144.069
OS07.6.A CONNEXIN-MEDIATED NETWORKS IN GLIOBLASTOMA COMMUNICATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v24, https://doi.org/10.1093/neuonc/noae144.070
OS07.7.A DISSECTING SPATIAL DIVERSITY OF GLIOBLASTOMA GENOTYPES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v24, https://doi.org/10.1093/neuonc/noae144.071
OS07.8.A INNOVATIVE DYNAMIC STRATIFICATION IN GLIOBLASTOMA: ANALYZING TUMOR CELL CHARACTERISTICS AND MOBILITY STRATEGIES THROUGH SINGLE CELL BEHAVIOR LIVE IMAGING (SCBLI)
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v24–v25, https://doi.org/10.1093/neuonc/noae144.072
OS07.9.A NETWORK ANALYSIS IDENTIFIES CSF2RA’S GENETIC COMMUNITY AS A REGULATOR OF PROGRESSION IN THE INVASIVE REGION OF HIGH GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v25, https://doi.org/10.1093/neuonc/noae144.073
OS08 Advances in diagnosis and treatment of skull base tumors
OS08.5.A THE ROLE OF FIBROBLAST ACTIVATION PROTEIN IN GLIOBLASTOMA AND GLIOSARCOMA - A COMPARISON OF TISSUE, 68GA-FAPI-46 POSITRON EMISSION TOMOGRAPHY AND SURVIVAL DATA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v25, https://doi.org/10.1093/neuonc/noae144.074
OS08.6.A MACHINE LEARNING BASED PREDICTIVE RADIOMICS FOR EVALUATION OF CANCER IMMUNE SIGNATURE IN GLIOBLASTOMA: THE PRECISE-GBM STUDY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v25, https://doi.org/10.1093/neuonc/noae144.075
OS08.7.A STIMULATED RAMAN HISTOLOGY FOR INTRAOPERATIVE DIAGNOSIS IN PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v26, https://doi.org/10.1093/neuonc/noae144.076
OS09 New target therapies in gliomas: TERT, ATRX, H3-K27M and TIM-3
OS09.5.A UNEXPECTED FUNCTIONAL ROLE OF GLYCOCALYX ENCAPSULATION DURING GBM METABOLIC ADAPTATION OPENS AVENUES FOR NEW TREATMENT CONCEPTS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v26, https://doi.org/10.1093/neuonc/noae144.077
OS09.6.A METHYLATION CLASSIFICATION AND MOLECULAR LANDSCAPE OF H3 WILDTYPE SPINAL CORD GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v26, https://doi.org/10.1093/neuonc/noae144.078
OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v26–v27, https://doi.org/10.1093/neuonc/noae144.079
OS10 Symptomatic and asymptomatic brain metastasis: consensus and implications for therapy
OS10.4.A CXCL1 MEDIATES LEPTOMENINGEAL METASTASIS GROWTH
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v27, https://doi.org/10.1093/neuonc/noae144.080
OS10.5.A MINIMALLY INVASIVE BRAIN METASTASES ARE CHARACTERIZED BY AN ACTIVE, ANTI-CANCER IMMUNE INFILTRATE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v27, https://doi.org/10.1093/neuonc/noae144.081
OS10.6.A THE IMPACT OF PATIENT-REPORT OUTCOME QUESTIONNAIRE PARTICIPATION ON OVERALL SURVIVAL IN PATIENTS WITH BRAIN METASTASES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v27–v28, https://doi.org/10.1093/neuonc/noae144.082
OS11 Impact of variables from the host in neuro-oncology research
OS11.5.A MYELOID CELLS DRIVE IMMUNOSUPPRESSION OF CHIMERIC ANTIGEN RECEPTOR T CELLS IN THE NEURONAL MICROENVIRONMENT OF GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v28, https://doi.org/10.1093/neuonc/noae144.083
OS11.6.A GEMISTOCYTIC TUMOR CELLS AND IMMUNE REACTIVE MICROGLIA PROGRAMMED FOR GLIAL SCARRING CHARACTERIZE T CELL CONTAINMENT IN IDH-MUTANT ASTROCYTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v28, https://doi.org/10.1093/neuonc/noae144.084
OS11.7.A DELETION OF MONOCARBOXYLATE TRANSPORTER 1 IN MYELOID CELLS FAVOURS GLIOBLASTOMA DEVELOPMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v28–v29, https://doi.org/10.1093/neuonc/noae144.085
OS12 Efforts to improve management of incidental brain tumors
OS12.5.A IMPROVING HEALTH EDUCATION FOR BRAIN TUMOR PATIENTS AND RELATIVES THROUGH ANIMATED AND VISUAL INFORMATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v29, https://doi.org/10.1093/neuonc/noae144.086
OS12.6.A MOLECULAR GLIOBLASTOMAS - BETTER PROGNOSIS AFTER CORRECTING FOR TREATMENT DIFFERENCES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v29–v30, https://doi.org/10.1093/neuonc/noae144.087
OS12.7.A INTEGRATED DIGITAL PATHOLOGY AND TRANSCRIPTOMIC ANALYSIS OF ADULT GLIOMAS WITH HIGH LYMPHOCYTE INFILTRATION IDENTIFIES CELLULAR AND SPATIAL DETERMINANTS OF IMMUNE INFILTRATION WITH PROGNOSTIC VALUE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v30, https://doi.org/10.1093/neuonc/noae144.088
POSTER PRESENTATIONS
P01 Tumor heterogeneity and plasticity
P01.01.A CHARACTERIZATION OF GLIOBLASTOMA’S MIGRATION HETEROGENEITY THROUGH A PATIENT-DERIVED 3D MODEL
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v30, https://doi.org/10.1093/neuonc/noae144.089
P01.02.B CLONAL ARCHITECTURE, 3D TUMOR GROWTH, TRANSCRIPTIONAL STATES AND IN-VITRO DRUG RESPONSE IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v30, https://doi.org/10.1093/neuonc/noae144.090
P01.03.A DECIPHERING THE TUMOUR ECOSYSTEM IN GLIOMAS USING SPATIAL TRANSCRIPTOMICS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v30–v31, https://doi.org/10.1093/neuonc/noae144.091
P01.04.B DISSECT THE ROLE OF DRIVER GENE MUTATIONS IN THE INITIATION AND PROGRESSION OF GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v31, https://doi.org/10.1093/neuonc/noae144.092
P01.05.A DRUG-RESPONSE ANALYSIS AND SINGLE NUCLEUS RNA SEQUENCING ON PATIENT-DERIVED NEUROSPHERES TO REVEAL DRUG RESPONSE AND RESISTANCE MECHANISMS IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v31, https://doi.org/10.1093/neuonc/noae144.093
P01.06.B GLIOMA STEM CELLS REMODEL ASTROCYTES TO FACILITATE GBM PROGRESSION VIA EXOSOMAL ZNF16 ACTIVATED TGF-Β SIGNALING AXIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v31, https://doi.org/10.1093/neuonc/noae144.094
P01.07.A HOW IS A RECURRENT GLIOBLASTOMA SELECTED?
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v32, https://doi.org/10.1093/neuonc/noae144.095
P01.08.A HYOXIA-INDUCED EXPRESSION OF ARHGAP FAMILY MEMBERS PROMOTES GLIOBLASTOMA DISSEMINATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v32, https://doi.org/10.1093/neuonc/noae144.096
P01.09.B IDENTIFICATION OF TIME-DEPENDENT PHENOTYPIC SHIFTS IN PATIENT-DERIVED GLIOMA STEM-LIKE CELLS AFTER CHEMORADIOTHERAPY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v32, https://doi.org/10.1093/neuonc/noae144.097
P01.10.A INVESTIGATING GLIOBLASTOMA BIOMARKERS IN THE INFILTRATION ZONE: TOPOGRAPHIC LINKS TO AN EARLY RELAPSE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v32, https://doi.org/10.1093/neuonc/noae144.098
P01.11.B PATIENT-DERIVED GLIOBLASTOMA CELLS ARE CAPABLE OF FORMING TUBE-LIKE STRUCTURES IN VITRO SUGGESTIVE OF VASCULOGENIC MIMICRY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v32–v33, https://doi.org/10.1093/neuonc/noae144.099
P01.12.A PERSISTENT GENETIC AND EPIGENETIC CHANGES ARE INDUCED BY INVASION STIMULI IN GLIOBLASTOMA CELLS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v33, https://doi.org/10.1093/neuonc/noae144.100
P01.13.B SPATIALLY RESOLVED FUNCTIONAL PROFILING FOR GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v33, https://doi.org/10.1093/neuonc/noae144.101
P01.14.B SYNGN: A NOVEL EPIGENETIC PLATFORM TO DISCOVER PATIENT-SPECIFIC DISEASE MECHANISMS AND DRUGGABLE TARGETS IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v33, https://doi.org/10.1093/neuonc/noae144.102
P01.15.A SURGICAL RESECTION-INDUCED ISCHEMIA DRIVES GLIOBLASTOMA CELL PLASTICITY AND TUMOR MICROENVIRONMENT ADAPTATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v34, https://doi.org/10.1093/neuonc/noae144.103
P02 Tumor microenvironment
P02.01.B 3-PHOTON IN VIVO IMAGING REVEALS BREAKDOWN OF MICROGLIA SURVEILLANCE UPON GLIOMA INVASION IN THE CORPUS CALLOSUM
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v34, https://doi.org/10.1093/neuonc/noae144.104
P02.02.A AN MRI-LSM PLATFORM TO ASSESS BLOOD-BRAIN BARRIER DISRUPTION AND BIODISTRIBUTION OF IMMUNOTHERAPIES IN EXPERIMENTAL GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v34, https://doi.org/10.1093/neuonc/noae144.105
P02.03.A BLOOD-BRAIN BARRIER AFFECTING THE METABOLOMICS PROFILES IN THE TUMOR MICROENVIRONMENT, CSF AND BLOOD OF IN VIVO HUMAN GLIOBLASTOMA XENOGRAFT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v34–v35, https://doi.org/10.1093/neuonc/noae144.106
P02.04.B CANCER-ASSOCIATED FIBROBLASTS IN LUNG CANCER BRAIN METASTASES: EFFECT ON CANCER CELL MIGRATION AND INVASION, AND MONOCYTE RECRUITMENT AND DIFFERENTIATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v35, https://doi.org/10.1093/neuonc/noae144.107
P02.05.A COMPREHENSIVE ANALYSIS OF TUMOR-ASSOCIATED MACROPHAGES IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v35, https://doi.org/10.1093/neuonc/noae144.108
P02.06.B CROSSTALK BETWEEN GLIOMA AND MYELOID SHAPES DISTINCT TUMOR MICROENVIRONMENT IN SPINAL CORD, BRAIN STEM AND CEREBRUM
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v35, https://doi.org/10.1093/neuonc/noae144.109
P02.07.B FIBROBLAST ACTIVATION PROTEIN EXPRESSING MESENCHYMAL CELLS INFLUENCE T CELL ABUNDANCE AND FUNCTION IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v35–v36, https://doi.org/10.1093/neuonc/noae144.110
P02.08.A HERV-W ENVELOPE PROTEIN IS PRESENT IN MICROGLIAL CELLS OF THE HUMAN GLIOMA TUMOR MICROENVIRONMENT AND DIFFERENTIALLY MODULATES NEOPLASTIC CELL BEHAVIOR
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v36, https://doi.org/10.1093/neuonc/noae144.111
P02.09.B HYPOXIA MODULATES DIFFUSE ASTROCYTOMA TUMOR MICROENVIRONMENT THROUGH CELL-TYPE-DEPENDENT RESPONSES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v36, https://doi.org/10.1093/neuonc/noae144.112
P02.10.A IDENTIFYING NOVEL HEXOKINASE-2 ASSOCIATED PROCESSES IN THE GLIOBLASTOMA TUMOUR MICROENVIRONMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v36–v37, https://doi.org/10.1093/neuonc/noae144.113
P02.11.A IMMUNE CELLS SUBPOPULATIONS IN PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v37, https://doi.org/10.1093/neuonc/noae144.114
P02.12.B IMMUNOMODULATORY EFFECT OF MESENCHYMAL CELLS ON T-LYMPHOCYTES IN A 3D SPHEROID MODEL OF GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v37, https://doi.org/10.1093/neuonc/noae144.115
P02.13.B IMPLEMENTATION OF A MULTIPLEXED TISSUE IMAGING PROTOCOL FOR CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT IN MELANOMA BRAIN METASTASES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v37, https://doi.org/10.1093/neuonc/noae144.116
P02.14.B INCREASED PRE-OPERATIVE MEAN PLATELET VOLUME (MPV) IS ASSOCIATED WITH GLIOBLASTOMA IDH-WTOVERALL SURVIVAL, PRELIMINARY DATA FROM 167 PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v38, https://doi.org/10.1093/neuonc/noae144.117
P02.15.A INVESTIGATING THE ROLE OF CELLULAR SENESCENCE IN BRIDGING GLIOBLASTOMA AND ALZHEIMER’S DISEASE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v38, https://doi.org/10.1093/neuonc/noae144.118
P02.16.A IRF8-DRIVEN REPROGRAMMING OF THE IMMUNE MICROENVIRONMENT ENHANCES ANTI-TUMOR ADAPTIVE IMMUNITY AND REDUCES IMMUNOSUPPRESSION IN MURINE GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v38, https://doi.org/10.1093/neuonc/noae144.119
P02.17.B MANIPULATING GABAERGIC MECHANISMS TO DELAY GLIOMA INVASION IN PERITUMORAL MICROENVIRONMENT
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v38–v39, https://doi.org/10.1093/neuonc/noae144.120
P02.18.A MOLECULAR CHANGES UNDERLYING DECAY OF SENSORY RESPONSES AND ENHANCED SEIZURE PROPENSITY IN PERITUMORAL NEURONS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v39, https://doi.org/10.1093/neuonc/noae144.121
P02.19.B NEW MURINE MODEL OF GLIOBLASTOMA SHOWS SUPPRESSIVE IMMUNE INFILTRATION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v39, https://doi.org/10.1093/neuonc/noae144.122
P02.20.A NICHE-DEPENDENT MODES OF IMMUNE CELL TRAFFICKING IN GLIOBLASTOMA OFFER TARGETS FOR NOVEL IMMUNOTHERAPIES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v39, https://doi.org/10.1093/neuonc/noae144.123
P02.21.A PROGNOSTIC ROLE OF CD68 AND CD163 IN GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v39–v40, https://doi.org/10.1093/neuonc/noae144.124
P02.22.A REARRANGEMENTS OF PERITUMORAL TISSUE THAT OCCUR ALONG WITH GLIOMA PROGRESSION
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v40, https://doi.org/10.1093/neuonc/noae144.125
P02.23.A SPATIAL PROFILING OF THE MYELOID COMPARTMENT IN MENINGIOMA REVEALS DISTINCT PHENOTYPIC HETEROGENEITY ACROSS METHYLATION CLASSES
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v40, https://doi.org/10.1093/neuonc/noae144.126
P02.24.B THE IMPACT OF THE IDH1 R132H MUTATION ON MMP2 METHYLATION, EXPRESSION AND INVASION IN EXPERIMENTAL GLIOMAS AND HUMAN GBMS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v40, https://doi.org/10.1093/neuonc/noae144.127
P02.25.A TUMOR MICROENVIRONMENT (TME) VIS-À-VIS ANTI-VASCULAR TREATMENT IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v40–v41, https://doi.org/10.1093/neuonc/noae144.128
P03 Cancer-Neuroscience
P03.01.A ANDROGEN MODULATION OF TEMOZOLOMIDE SENSITIVITY IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v41, https://doi.org/10.1093/neuonc/noae144.129
P03.02.B DECIPHERING THE IDENTITY AND CHARACTERISTICS OF LONG-TERM LABEL RETAINING GLIOBLASTOMA CELLS AND THEIR ROLE IN TUMOUR RELAPSE
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v41, https://doi.org/10.1093/neuonc/noae144.130
P03.03.A GAMMAKNIFE RADIOSURGERY FOR VESTIBULAR SCHWANNOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v41–v42, https://doi.org/10.1093/neuonc/noae144.131
P04 Metabolism
P04.01.B DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v42, https://doi.org/10.1093/neuonc/noae144.132
P04.02.A DISCOVERY OF NEW METABOLIC PATHWAYS IMPLICATED IN THERAPY RESISTANCE IN GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v42, https://doi.org/10.1093/neuonc/noae144.133
P04.03.A TARGETING SCD TRIGGERS LIPOTOXICITY OF CANCER CELLS AND ENHANCES ANTI-TUMOR IMMUNITY IN BREAST CANCER BRAIN METASTASIS MOUSE MODELS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v42, https://doi.org/10.1093/neuonc/noae144.134
P04.04.B THE FUNCTIONS AND MECHANISMS OF OSGIN1 INVOLVED IN FERROPTOSIS RESISTANCE OF GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v42–v43, https://doi.org/10.1093/neuonc/noae144.135
P05 DNA damage
P05.01.A ATR INHIBITORS INCREASE THE ANTI-PROLIFERATIVE EFFECTS OF STANDARD TREATMENT ON PATIENT-DERIVED GLIOBLASTOMA CELLS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v43, https://doi.org/10.1093/neuonc/noae144.136
P05.02.B MOLECULAR MECHANISMS OF ANEUPLOIDY AND GLIOBLASTOMA AGGRESSIVENESS INDUCED BY DIAPH3 LOSS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v43, https://doi.org/10.1093/neuonc/noae144.137
P06 New targets
P06.01.A TARGETING MRNA DECAPPING ENZYME SCAVENGER (DCPS) IS A PROMISING STRATEGY AGAINST GLIOBLASTOMA VIA THE DOWN-REGULATION OF STAT5B
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v43, https://doi.org/10.1093/neuonc/noae144.138
P06.02.B DECODING THE DIVERSE SURFACEOME LANDSCAPE IN MALIGNANT BRAIN TUMORS IDENTIFIES TARGET CANDIDATES FOR PERSONALIZED IMMUNOTHERAPY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v43–v44, https://doi.org/10.1093/neuonc/noae144.139
P06.03.A EXPLORING THE THERAPEUTIC EFFICACY OF CHLOROQUINE AND HYDROXYCHLOROQUINE IN IDH-WILDTYPE AND IDH-MUTANT GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v44, https://doi.org/10.1093/neuonc/noae144.140
P06.04.A FIRST IN HUMAN - TARGETING ANDROGEN RECEPTOR FOR GLIOBLASTOMA THERAPY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v44, https://doi.org/10.1093/neuonc/noae144.141
P06.05.B FLYDENTIFICATION - CHARACTERIZATION OF NOVEL MOLECULAR DRIVERS IN GLIOBLASTOMA BASED ON FUNCTIONAL GENOMICS SCREENING IN DROSOPHILA MELANOGASTER
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v44, https://doi.org/10.1093/neuonc/noae144.142
P06.06.A HOXA1, A TRANSCRIPTION FACTOR UPREGULATED IN GLIOBLASTOMA, IS ABLE TO TRAVEL BETWEEN CELLS WITH THEIR NUCLEI AS TARGET
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v44, https://doi.org/10.1093/neuonc/noae144.143
P06.07.B IDENTIFYING TARGETABLE ALTERATIONS PREDICTIVE OF DISTANT PROGRESSION IN GLIOBLASTOMA PATIENTS UNDERGOING STANDARD THERAPY
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v45, https://doi.org/10.1093/neuonc/noae144.144
P06.08.B OF TRAVELING HOMEOPROTEINS AND MEDULLOBLASTOMAS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v45, https://doi.org/10.1093/neuonc/noae144.145
P06.09.B RATIONAL DRUG COMBINATIONS TARGETING FAK AND MEK OVERCOMES TUMOUR HETEROGENEITY IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v45, https://doi.org/10.1093/neuonc/noae144.146
P06.10.A THE MIRNA 216B-5P ACTS AS A PROMISING TUMOR-SUPPRESSOR BY MANIPULATING CELL CYCLE PROGRESSION IN HIGH-GRADE GLIOMA CELLS
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v45–v46, https://doi.org/10.1093/neuonc/noae144.147
P06.11.A TUTOR: A MULTICENTER, PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v46, https://doi.org/10.1093/neuonc/noae144.148
P06.12.B Microbiota-gut-brain axis in glioblastoma development and therapeutic resistance
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Page v46, https://doi.org/10.1093/neuonc/noae144.149
P07 Sex-related influence on brain tumors
P07.01.B ANDROGEN RECEPTOR SIGNALING MODULATES BOTH TUMOR AND IMMUNE CELLS IN GLIOBLASTOMA AND IMPACTS GLIOBLASTOMA GROWTH
Neuro-Oncology, Volume 26, Issue Supplement_5, October 2024, Pages v46–v47, https://doi.org/10.1093/neuonc/noae144.150
